First patient with refractory lupus nephritis treated with irinotecan New publication in the Scandinavian Journal of Rheumatology 2021-11- 2
Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapy
New Research Funding for LUNIRI 2018-08-21
Steffen Frese, the founder of LUNIRI, received new research funding from the German Research Foundation. http://gepris.dfg.de/gepris/projekt/317392477?language=en
Research will be conducted at the German Rheumatism Research Centre in Berlin, Germany.&nb ... Read More
Berlin Marathon 2017 Running for lupus. Running for the new treatment. 2017-09-27
LUNIRI in the News Lupus Nephritis and Irinotecan at LUPUSNEWSTODAY.COM 2016-11-30
http://lupusnewstoday.com/2016/11/11/irinotecan-topo-1-blocker-seen-as-potential-lupus-specific-treatment
Neue Ergebnisse aus der Forschung veröffentlich in Arthritis Research & Therapy Wir konnten zeigen, dass Irinotecan in einem zweiten Model von spontaner Lupuserkrankung sowohl die Nieren- als auch die Hautbeteiligung effektiv unterdrückt. 2016-10-25
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243
New scientific data published in Arthritis Research & Therapy Irinotecan efficiently suppressed both lupus nephritis and skin lesions in a second and genetically different model of spontaneous SLE 2016-10-25
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243
More Blog Entries 
